Subscribe
istock-693373540_natali_mis
Natali_Mis / iStockphoto.com
7 March 2018Europe

EPO grants second CRISPR patent to ERS Genomics

The European Patent Office (EPO) has granted a second CRISPR/Cas9 patent to a specialist genomics company, one month after revoking the Broad Institute of Harvard and MIT’s patent relating to the technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
USPTO grants another CRISPR patent to Charpentier
12 March 2019   The US Patent and Trademark Office has issued a third CRISPR patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.
Biotechnology
ERS Genomics signs CRISPR patent deal on industrial applications
16 October 2018   ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
Americas
USPTO grants Charpentier-founded company first CRISPR patent
20 June 2018   The US Patent and Trademark Office has granted ERS Genomics its first US patent covering the use of CRISPR/Cas9 technology for gene editing.


Editor's picks

Trouble at the USPTO—Part II: Bracing for impact
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025

Editor's picks

Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
3 March 2025
Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025

More on this story

Americas
USPTO grants another CRISPR patent to Charpentier
12 March 2019   The US Patent and Trademark Office has issued a third CRISPR patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.
Biotechnology
ERS Genomics signs CRISPR patent deal on industrial applications
16 October 2018   ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
Americas
USPTO grants Charpentier-founded company first CRISPR patent
20 June 2018   The US Patent and Trademark Office has granted ERS Genomics its first US patent covering the use of CRISPR/Cas9 technology for gene editing.

More on this story

Americas
USPTO grants another CRISPR patent to Charpentier
12 March 2019   The US Patent and Trademark Office has issued a third CRISPR patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.
Biotechnology
ERS Genomics signs CRISPR patent deal on industrial applications
16 October 2018   ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
Americas
USPTO grants Charpentier-founded company first CRISPR patent
20 June 2018   The US Patent and Trademark Office has granted ERS Genomics its first US patent covering the use of CRISPR/Cas9 technology for gene editing.

More features

Patent cliff: 5 blockbusters running out of road
Herbert Smith Freehills expands German tech patent team
‘Always new twists’: Bayer legal team on defending a $4bn drug
Novartis and MSN feud intensifies after Fed Circ denies rehearing
EU court signals tough stance on ‘pay-for-delay’ pharma deals
Panitch Schwarze hires experienced ex-USPTO examiner
Fed Circ affirms generic’s litigation costs of $12m are tax-deductible
Genmab fights claim over 'secrets theft' behind $1.8bn takeover